Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sean Tu

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|September 26, 2022
Product Hopping in the Drug Industry - Lessons from AlbuterolOlivier J Wouters, William B Feldman, S Sean Tu
IEEE Pulse|October 10, 2023
Next-Generation Bioprinted Products: Products of Nature or Patentable Innovation?Jennie O Zheng, S Sean Tu, Stephen B Maebius
JAMA|April 9, 2026
Skinny Labels at the Supreme Court-Generic Competition, Patent Inducement, and Affordable MedicinesS Sean Tu, Frazer A Tessema, Aaron S Kesselheim
The New England Journal of Medicine|November 27, 2024
Clearing Dense Drug-Patent ThicketsBernard Chao, Ryan Whalen, Aaron S Kesselheim, et al.
JAMA|February 22, 2024
Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic CompetitionAmeet Sarpatwari, Sajeev Kohli, S Sean Tu, et al.
JAMA|March 27, 2023
Broad Patent Claims Come Before the Supreme Court in Amgen v SanofiS Sean Tu, Sarosh Nagar, Victor L Van de Wiele
Nature Biotechnology|March 16, 2024
Biologic patent challenges under the America Invents ActVictor L Van de Wiele, Aaron S Kesselheim, S Sean Tu
JAMA|December 1, 2025
Combination-Only Approvals as a Barrier to Affordable HIV CareS Sean Tu, Timothy Bonis, Michael S Sinha, et al.
Journal of Law and the Biosciences|January 6, 2025
Accelerating biosimilar market access: the case for allowing earlier standingS Sean Tu, Rachel Goode, Matthew Turner, et al.
JAMA Internal Medicine|June 8, 2026
Early Generic Semaglutide in Canada-Implications for US Patients and PolicyS Sean Tu, Aaron S Kesselheim, Mina Tadrous, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|September 26, 2022
Product Hopping in the Drug Industry - Lessons from AlbuterolOlivier J Wouters, William B Feldman, S Sean Tu
IEEE Pulse|October 10, 2023
Next-Generation Bioprinted Products: Products of Nature or Patentable Innovation?Jennie O Zheng, S Sean Tu, Stephen B Maebius
JAMA|April 9, 2026
Skinny Labels at the Supreme Court-Generic Competition, Patent Inducement, and Affordable MedicinesS Sean Tu, Frazer A Tessema, Aaron S Kesselheim
The New England Journal of Medicine|November 27, 2024
Clearing Dense Drug-Patent ThicketsBernard Chao, Ryan Whalen, Aaron S Kesselheim, et al.
JAMA|February 22, 2024
Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic CompetitionAmeet Sarpatwari, Sajeev Kohli, S Sean Tu, et al.
JAMA|March 27, 2023
Broad Patent Claims Come Before the Supreme Court in Amgen v SanofiS Sean Tu, Sarosh Nagar, Victor L Van de Wiele
Nature Biotechnology|March 16, 2024
Biologic patent challenges under the America Invents ActVictor L Van de Wiele, Aaron S Kesselheim, S Sean Tu
JAMA|December 1, 2025
Combination-Only Approvals as a Barrier to Affordable HIV CareS Sean Tu, Timothy Bonis, Michael S Sinha, et al.
Journal of Law and the Biosciences|January 6, 2025
Accelerating biosimilar market access: the case for allowing earlier standingS Sean Tu, Rachel Goode, Matthew Turner, et al.
JAMA Internal Medicine|June 8, 2026
Early Generic Semaglutide in Canada-Implications for US Patients and PolicyS Sean Tu, Aaron S Kesselheim, Mina Tadrous, et al.
Pageof 6